Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review
Introduction Studies on economic evaluations of the 13-valent pneumococcal conjugate vaccine (PCV13) have been increasing over the last decade. No systematic reviews have synthesized the evidence of economic evaluations of the PCV13. Areas covered We systematically searched the literature which publ...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/14760584.2023.2173176 |
| _version_ | 1827813137420648448 |
|---|---|
| author | Yuanze Du Yi Wang Ting Zhang Juanjuan Li Hewei Song Yuanyuan Wang Yifei Xu Jingwen Cui Ming Yang Zengwu Wang Xiuyun Wu Chunping Wang |
| author_facet | Yuanze Du Yi Wang Ting Zhang Juanjuan Li Hewei Song Yuanyuan Wang Yifei Xu Jingwen Cui Ming Yang Zengwu Wang Xiuyun Wu Chunping Wang |
| author_sort | Yuanze Du |
| collection | DOAJ |
| description | Introduction Studies on economic evaluations of the 13-valent pneumococcal conjugate vaccine (PCV13) have been increasing over the last decade. No systematic reviews have synthesized the evidence of economic evaluations of the PCV13. Areas covered We systematically searched the literature which published on peer-reviewed journals from January 2010 to June 2022. The literature search was conducted in the following electronic databases: PubMed, Web of Science, Embase, the Cochrane Library, CNKI, Wanfang database, VIP database. We identified 1827 records from the database search. After excluding 511 duplicates, 1314 records were screened, of which 156 records were retained for the full-text reviews. A total of 44 studies were included in the review. Among the included studies, 33 studies were economic evaluations of PCV13 among children, and 11 studies were conducted among adults. The literature search initiated in April, 2022, and updated in June 2022. Expert opinion Vaccination with PCV13 was found to significantly reduce the mortality and morbidity of pneumococcal diseases and was cost-effective compared to no vaccine or several other pneumococcal vaccines (e.g. PCV10, PPV23). Future research is advised to expand economic evaluations of PCV13 combined with dynamic model to enhance methodologic rigor and prediction accuracy. |
| first_indexed | 2024-03-11T23:28:31Z |
| format | Article |
| id | doaj.art-0fd3dfeebd8e4fd180feabc3654c6128 |
| institution | Directory Open Access Journal |
| issn | 1476-0584 1744-8395 |
| language | English |
| last_indexed | 2024-03-11T23:28:31Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj.art-0fd3dfeebd8e4fd180feabc3654c61282023-09-20T10:33:43ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952023-12-0122119320610.1080/14760584.2023.21731762173176Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic reviewYuanze Du0Yi Wang1Ting Zhang2Juanjuan Li3Hewei Song4Yuanyuan Wang5Yifei Xu6Jingwen Cui7Ming Yang8Zengwu Wang9Xiuyun Wu10Chunping Wang11Weifang Medical UniversityCenter for Disease Control and PreventionChinese Academy of Medical Sciences/ Peking Union Medical CollegeWeifang Medical UniversityWeifang Medical UniversityCenter for Disease Control and PreventionWeifang Medical UniversityWeifang Medical UniversityWeifang Medical UniversityWeifang People’s HospitalWeifang Medical UniversityWeifang Medical UniversityIntroduction Studies on economic evaluations of the 13-valent pneumococcal conjugate vaccine (PCV13) have been increasing over the last decade. No systematic reviews have synthesized the evidence of economic evaluations of the PCV13. Areas covered We systematically searched the literature which published on peer-reviewed journals from January 2010 to June 2022. The literature search was conducted in the following electronic databases: PubMed, Web of Science, Embase, the Cochrane Library, CNKI, Wanfang database, VIP database. We identified 1827 records from the database search. After excluding 511 duplicates, 1314 records were screened, of which 156 records were retained for the full-text reviews. A total of 44 studies were included in the review. Among the included studies, 33 studies were economic evaluations of PCV13 among children, and 11 studies were conducted among adults. The literature search initiated in April, 2022, and updated in June 2022. Expert opinion Vaccination with PCV13 was found to significantly reduce the mortality and morbidity of pneumococcal diseases and was cost-effective compared to no vaccine or several other pneumococcal vaccines (e.g. PCV10, PPV23). Future research is advised to expand economic evaluations of PCV13 combined with dynamic model to enhance methodologic rigor and prediction accuracy.http://dx.doi.org/10.1080/14760584.2023.217317613-valent pneumococcal conjugate vaccinepcv13cost-effectivenessincremental cost-effectiveness ratioicerquality-adjusted life-yearqalydisability-adjusted life-yeardalysystematic review |
| spellingShingle | Yuanze Du Yi Wang Ting Zhang Juanjuan Li Hewei Song Yuanyuan Wang Yifei Xu Jingwen Cui Ming Yang Zengwu Wang Xiuyun Wu Chunping Wang Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review Expert Review of Vaccines 13-valent pneumococcal conjugate vaccine pcv13 cost-effectiveness incremental cost-effectiveness ratio icer quality-adjusted life-year qaly disability-adjusted life-year daly systematic review |
| title | Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review |
| title_full | Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review |
| title_fullStr | Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review |
| title_full_unstemmed | Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review |
| title_short | Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review |
| title_sort | economic evaluations of 13 valent pneumococcal conjugate vaccine a systematic review |
| topic | 13-valent pneumococcal conjugate vaccine pcv13 cost-effectiveness incremental cost-effectiveness ratio icer quality-adjusted life-year qaly disability-adjusted life-year daly systematic review |
| url | http://dx.doi.org/10.1080/14760584.2023.2173176 |
| work_keys_str_mv | AT yuanzedu economicevaluationsof13valentpneumococcalconjugatevaccineasystematicreview AT yiwang economicevaluationsof13valentpneumococcalconjugatevaccineasystematicreview AT tingzhang economicevaluationsof13valentpneumococcalconjugatevaccineasystematicreview AT juanjuanli economicevaluationsof13valentpneumococcalconjugatevaccineasystematicreview AT heweisong economicevaluationsof13valentpneumococcalconjugatevaccineasystematicreview AT yuanyuanwang economicevaluationsof13valentpneumococcalconjugatevaccineasystematicreview AT yifeixu economicevaluationsof13valentpneumococcalconjugatevaccineasystematicreview AT jingwencui economicevaluationsof13valentpneumococcalconjugatevaccineasystematicreview AT mingyang economicevaluationsof13valentpneumococcalconjugatevaccineasystematicreview AT zengwuwang economicevaluationsof13valentpneumococcalconjugatevaccineasystematicreview AT xiuyunwu economicevaluationsof13valentpneumococcalconjugatevaccineasystematicreview AT chunpingwang economicevaluationsof13valentpneumococcalconjugatevaccineasystematicreview |